ArticleFrontiers in pharmacology2024
Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Adverse events associated with drug-related thiamine deficiency: A pharmacovigilance study.JPEN. Journal of parenteral and enteral nutrition · 2026Article
- Systematic analysis of adverse reaction signals induced by leflunomide, upadacitinib, and baricitinib in the treatment of rheumatoid arthritis: a FAERS database analysis.Frontiers in medicine · 2026Article
- Abnormal coagulation indicators associated with β-lactamantibacterial drug: a pharmacovigilance study based on the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A Real-World Disproportionality Analysis of Avacopan in Anti-Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System.Pharmacology research & perspectives · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drugs provides a valuable basis for enhancing clinical drug safety. Methods: The adverse event reports related to coagulopathies from Q1 2004 to Q2 2024 were extracted from the ASCII data packages in FAERS. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) were used to identify adverse drug reaction signals associated with coagulopathies. Results: During the reporting period, 40,545 reports were retrieved, with a slightly higher proportion of females than males. Among the top 30 drugs associated with the occurrence of coagulopathies, 24 drugs exhibited positive signals in risk analysis. Based on the individual drug reporting odds ratio (95% confidence interval) as a measure of risk signal strength, the top five drugs are as follows: gemcitabine [ROR (95% CI):16.87 (15.83-17.98)], busulfan [ROR (95% CI):15.51 (13.69-17.58)], anti-thymocyte globulin [ROR (95% CI):15.49 (13.49-17.78)], tacrolimus [ROR (95% CI):12.7 (11.57-13.95)], etonogestrel and ethinylestradiol vaginal ring [ROR (95% CI):11.88 (10.95-12.89)]. After categorizing the drugs, the strongest risk signal is sex hormones and modulators of the genital system [ROR (95% CI):11.88 (10.95-12.89)], followed by analgesics [ROR (95%CI): 6.73 (6.38-7.1)], immunosuppressants [ROR (95% CI):3.91 (3.76-4.05)], antineoplastic agents [ROR (95% CI):3.33 (3.22-3.45)], corticosteroids for systemic use [ROR (95% CI): 2.94 (2.73-3.18)], antiepileptics [ROR (95% CI):1.93 (1.71-2.18)], drugs used in diabetes [ROR (95% CI):1.5 (1.34-1.67)], antibacterials for systemic use [ROR (95% CI):1.46 (1.28-1.68)]. Conclusion: Our findings indicate that multiple drugs are associated with an increased risk of coagulopathies. From the pharmacovigilance perspective, proactive analysis of these drugs aids in clinical monitoring and enhances risk identification of coagulopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.